CN101716132B - 非布索坦肠溶制剂 - Google Patents
非布索坦肠溶制剂 Download PDFInfo
- Publication number
- CN101716132B CN101716132B CN2008102237228A CN200810223722A CN101716132B CN 101716132 B CN101716132 B CN 101716132B CN 2008102237228 A CN2008102237228 A CN 2008102237228A CN 200810223722 A CN200810223722 A CN 200810223722A CN 101716132 B CN101716132 B CN 101716132B
- Authority
- CN
- China
- Prior art keywords
- febuxostat
- enteric
- preparation
- composition
- sealing coat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 229960005101 febuxostat Drugs 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000002775 capsule Substances 0.000 claims abstract description 13
- -1 phthalate ester Chemical class 0.000 claims abstract description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 10
- 229960003943 hypromellose Drugs 0.000 claims abstract description 10
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims abstract description 6
- 238000007789 sealing Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 8
- 239000012055 enteric layer Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 4
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 229950010118 cellacefate Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001826 dimethylphthalate Drugs 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000004051 gastric juice Anatomy 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000001187 pylorus Anatomy 0.000 abstract description 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- HKQOBOMRSSHSTC-UHFFFAOYSA-N cellulose acetate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 HKQOBOMRSSHSTC-UHFFFAOYSA-N 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000008570 general process Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 23
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 23
- 229940116269 uric acid Drugs 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 12
- 229960003459 allopurinol Drugs 0.000 description 12
- 201000005569 Gout Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 108010093894 Xanthine oxidase Proteins 0.000 description 11
- 102100033220 Xanthine oxidase Human genes 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 7
- 229950000193 oteracil Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 6
- 238000009505 enteric coating Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940063451 febuxostat 80 mg Drugs 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007944 soluble tablet Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 108010012029 Guanine Deaminase Proteins 0.000 description 1
- 102000013587 Guanine deaminase Human genes 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
药动学参数 | 普通片 | 肠溶片 |
Cmax(μg/L) | 651.34±84.45 | 639.61±77.01 |
tmax(h) | 29.00±4.35 | 35.00±4.55 |
T1/2(h) | 6.07±1.51 | 6.50±1.83 |
AUC0-t(μg/h·L) | 127392.47±25473.48 | 126957.26±27422.78 |
AUC0-∞(μg/h·L) | 131266.51±38067.29 | 129374.27±33637.31 |
F0-t(%) | 99.66 | |
F0-∞(%) | 98.56 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102237228A CN101716132B (zh) | 2008-10-09 | 2008-10-09 | 非布索坦肠溶制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102237228A CN101716132B (zh) | 2008-10-09 | 2008-10-09 | 非布索坦肠溶制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101716132A CN101716132A (zh) | 2010-06-02 |
CN101716132B true CN101716132B (zh) | 2012-01-11 |
Family
ID=42430829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102237228A Active CN101716132B (zh) | 2008-10-09 | 2008-10-09 | 非布索坦肠溶制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101716132B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20130574A1 (es) * | 2010-06-16 | 2013-06-01 | Takeda Pharmaceuticals Usa Inc | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa |
CN102895210B (zh) * | 2011-12-15 | 2014-08-06 | 宁夏康亚药业有限公司 | 改善了溶出度的非布司他片剂 |
CN102614145B (zh) * | 2012-04-28 | 2013-05-01 | 杭州朱养心药业有限公司 | 稳定的非布索坦片剂及其制备方法 |
CN102614146B (zh) * | 2012-04-28 | 2013-06-12 | 杭州朱养心药业有限公司 | 制备非布索坦片的方法和非布索坦片 |
CN102973530B (zh) * | 2012-12-14 | 2016-08-03 | 贵州信邦制药股份有限公司 | 一种非布索坦双层肠溶片剂及其制备方法 |
CN106667966A (zh) * | 2017-02-14 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | 一种微孔膜控释包衣非布索坦微丸及其制备方法 |
CN106667956A (zh) * | 2017-02-16 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | 一种非布索坦软胶囊制剂及其制备工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1954814A (zh) * | 2005-10-26 | 2007-05-02 | 重庆医药工业研究院有限责任公司 | 一种具有协同作用治疗痛风的药物组合物及其制备方法 |
CN101085761A (zh) * | 2007-06-29 | 2007-12-12 | 上海华拓医药科技发展股份有限公司 | 非布他特微晶及其组合物 |
-
2008
- 2008-10-09 CN CN2008102237228A patent/CN101716132B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1954814A (zh) * | 2005-10-26 | 2007-05-02 | 重庆医药工业研究院有限责任公司 | 一种具有协同作用治疗痛风的药物组合物及其制备方法 |
CN101085761A (zh) * | 2007-06-29 | 2007-12-12 | 上海华拓医药科技发展股份有限公司 | 非布他特微晶及其组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN101716132A (zh) | 2010-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101716132B (zh) | 非布索坦肠溶制剂 | |
KR101931195B1 (ko) | 올메사탄 메독소밀 및 로수바스타틴 또는 그의 염을 포함하는 약학 조성물 | |
JP6976946B2 (ja) | 生理活性の強い、urat1のインヒビターを含む医薬組成物 | |
CN104940156B (zh) | 依帕司他肠溶缓释片及其制备方法 | |
CN103417505A (zh) | 具有双相释药行为的石杉碱甲控释制剂及其制备方法 | |
CN103142552A (zh) | 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法 | |
CN103479592B (zh) | 一种盐酸二甲双胍缓释片及其制备方法 | |
KR20090114320A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
CN1682719B (zh) | 一种含有石杉碱甲的肠溶包衣缓释片剂及制备方法 | |
CN100488515C (zh) | 一种地红霉素肠溶微丸及制备方法 | |
CN105326814A (zh) | 托吡酯缓释制剂药物组合物 | |
CN107432869A (zh) | 包含盐酸二甲双胍和恩格列净的双层片及其制备方法 | |
CN112138007B (zh) | 氧化小檗碱在制备代谢性疾病药物中的应用及包含氧化小檗碱的药物组合物 | |
CN101990427A (zh) | 米格列奈及二甲双胍的复合制剂及其制造方法 | |
CN102600451B (zh) | 一种非洛地平雷米普利复方缓释制剂及其制备方法 | |
CN102106856B (zh) | 恩替卡韦药物组合物及其制备方法 | |
US10314794B2 (en) | Metoprolol sustained-release composition and preparation method thereof | |
CN101773482B (zh) | 一种三段式脉冲释药控释片及其制备方法 | |
CN101332178B (zh) | 一种用于口服的达非那新或其药用盐的药物制剂 | |
WO2019230937A1 (ja) | 溶出性に優れた経口固形製剤 | |
CN102552214A (zh) | 一种艾普拉唑肠溶胶囊及其制备方法 | |
CN101468021A (zh) | 头孢布烯结肠定位肠溶片 | |
KR20090107959A (ko) | 약제학적 제제 | |
CN1915233B (zh) | 一种治疗焦虑症的药物组合物及其口崩制剂 | |
CN104147012B (zh) | 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Cao Dandan Document name: Notification that Application Deemed not to be Proposed |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING KONRUNS PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING FANGCE FANGCHENG MEDICAL TECHNOLOGY CO., LTD. Effective date: 20130812 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130812 Address after: 100085 A building, 9 Ka Wah building, No. 7, 3rd Street, Beijing, 707 Patentee after: Konruns Pharmaceutical Co., Ltd. Address before: 100085 A, block A709, Ka Wah building, No. 9, 3rd Street, Beijing, Haidian District Patentee before: Beijing Fangce Equation Pharmaceutical Sci. & Tech. Co., Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100085 A building, 9 Ka Wah building, No. 7, 3rd Street, Beijing, 707 Patentee after: BEIJING KONRUNS PHARMACEUTICAL CO., LTD. Address before: 100085 A building, 9 Ka Wah building, No. 7, 3rd Street, Beijing, 707 Patentee before: Konruns Pharmaceutical Co., Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150918 Address after: 546700 tung oil industrial zone, Mengshan County, the Guangxi Zhuang Autonomous Region Patentee after: Guangxi Mengshan Biological Technology Co Ltd Address before: 100085 A building, 9 Ka Wah building, No. 7, 3rd Street, Beijing, 707 Patentee before: BEIJING KONRUNS PHARMACEUTICAL CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160406 Address after: 101500 Miyun Economic Development Zone, Beijing, No. 11 South Road Patentee after: BEIJING KONRUNS PHARMACEUTICAL CO., LTD. Address before: 546700 tung oil industrial zone, Mengshan County, the Guangxi Zhuang Autonomous Region Patentee before: Guangxi Mengshan Biological Technology Co Ltd |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210108 Address after: A710b, floor 7 (6), block a, 9 Shangdi 3rd Street, Haidian District, Beijing Patentee after: BEIJING KANGCHEN MEDICINE TECHNOLOGY Co.,Ltd. Address before: 101500 No.11, Xingsheng South Road, Miyun Economic Development Zone, Beijing Patentee before: BEIJING KONRUNS PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |